Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

The popularity of the affordable and durable Vulcanite frames, Bausch's skill and inventiveness, and Lomb's continued support and leadership enabled the company to thrive. By the 1870s, water-powered ...

Health officials, investigating the incidence of fungal infection in Bausch and Lomb lens wearers are still confused about the cause of the infection. The only association arrived at is that ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported ...

Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues Bausch + Lomb is exploring a sale as its parent company, Bausch Health ...

Bausch + Lomb Corp (NYSE:BLCO ... The world’s largest contact lens supplier, valued at over $10 billion, has sought advice from Goldman Sachs to explore interest from private equity firms.